Rehmann Capital Advisory Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Rehmann Capital Advisory Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$100K	Hold	10,041	–	–	﹤0.01%	691
2026 Q1	$95.6K	Buy	+10,041	New	+$78K	0.01%	667
2025 Q4	–	Sell	-10,141	Closed	-$77K	–	657
2025 Q3	$77K	Hold	10,141	–	–	﹤0.01%	630
2025 Q2	$90.9K	Sell	10,141 -1,375	-12%	-$12.8K	0.01%	604
2025 Q1	$86.4K	Hold	11,516	–	–	0.01%	598
2024 Q4	$86.6K	Sell	11,516 -450	-4%	-$3.42K	0.01%	593
2024 Q3	$90.9K	Sell	11,966 -33	-0.3%	-$251	0.01%	589
2024 Q2	$74.2K	Sell	11,999 -75	-0.6%	-$414	0.01%	572
2024 Q1	$61.3K	Hold	12,074	–	–	﹤0.01%	569
2023 Q4	$72.3K	Sell	12,074 -67	-0.6%	-$388	0.01%	548
2023 Q3	$86K	Hold	12,141	–	–	0.01%	509
2023 Q2	$85.5K	Hold	12,141	–	–	0.01%	530
2023 Q1	$101K	Hold	12,141	–	–	0.01%	526
2022 Q4	$139K	Hold	12,141	–	–	0.01%	528
2022 Q3	$153K	Hold	12,141	–	–	0.02%	499
2022 Q2	$128K	Hold	12,141	–	–	0.01%	481
2022 Q1	$197K	Hold	12,141	–	–	0.02%	508
2021 Q4	$168K	Buy	+12,141	New	+$161K	0.02%	532

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Rehmann Capital Advisory Group's BCRX Position: Q2 2026 in Review

Rehmann Capital Advisory Group held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 10,041 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #691.

Rehmann Capital Advisory Group first reported a position in BCRX in Q4 2021 and has held it in 18 quarters since. The position peaked at $197K in Q1 2022. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Rehmann Capital Advisory Group held 10,041 shares of BioCryst Pharmaceuticals worth $100K as of Q2 2026.
Rehmann Capital Advisory Group left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q2 2026, its #691 holding.
Rehmann Capital Advisory Group first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
Rehmann Capital Advisory Group's BioCryst Pharmaceuticals position peaked at $197K in Q1 2022.
319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q2 2026, filed 20 Aug 2026.